The Science of the "Unglueing": Biology and Diagnosis of PV
At a Glance
Pemphigus Vulgaris (PV) is an autoimmune disease where antibodies attack the proteins holding your skin cells together. This causes a separation called acantholysis, leading to shallow blisters. Doctors use biopsies to confirm PV and distinguish it from deeper blistering diseases.
While the symptoms of Pemphigus Vulgaris (PV) are visible on the surface, the disease itself is driven by a complex biological “misunderstanding” deep within your tissues. Understanding the cellular mechanics of PV can help you make sense of why it affects certain parts of your body and how your doctors choose the right medications to treat it.
The Biology of “Acantholysis”
In healthy skin and mucous membranes (like the lining of your mouth), cells are held together by specialized “glue” proteins called desmogleins. You can think of these proteins as the tiny snaps or staples that keep your skin cells in a tight, protective barrier [1].
In PV, your immune system mistakenly produces autoantibodies—proteins that attack these snaps. Specifically, they target Desmoglein 3 (Dsg3) and Desmoglein 1 (Dsg1) [2]. When these autoantibodies bind to the desmogleins, they cause the cells to pull apart from one another. This biological “unglueing” is called acantholysis [1][3]. Because the cells are no longer connected, fluid leaks into the gaps, creating the fragile blisters and painful erosions characteristic of the disease [4].
Telling PV Apart from Other Conditions
Because many autoimmune diseases cause blisters, doctors use biopsies and blood tests to distinguish PV from “look-alike” conditions like Bullous Pemphigoid (BP) and Mucous Membrane Pemphigoid (MMP).
| Feature | Pemphigus Vulgaris (PV) | Bullous Pemphigoid (BP) | Mucous Membrane Pemphigoid (MMP) |
|---|---|---|---|
| Blister Depth | Intraepidermal (shallow, inside the top layer) [5] | Subepidermal (deep, under the top layer) [5] | Subepidermal (deep, under the top layer) [6] |
| Cell Connection | Attacks the “snaps” between cells (desmosomes) [6] | Attacks the “anchors” to the base layer (hemidesmosomes) [6] | Attacks the “anchors” to the base layer (hemidesmosomes) [7] |
| Scarring | Typically no scarring [8] | Typically no scarring [8] | High risk of scarring, especially in eyes/mouth [9] |
| Blister Type | Flaccid (soft, breaks easily) [4] | Tense (firm, like a bubble) [6] | Variable, but often leads to scarring [9] |
Why Depth Matters
The distinction between intraepidermal (shallow) and subepidermal (deep) is critical for treatment. Because PV is intraepidermal and caused by specific antibodies in the blood, treatments like Rituximab (which targets the cells making those antibodies) are highly effective [10]. Subepidermal diseases like BP may be managed with different approaches, such as strong topical steroid creams [11]. Correctly identifying the depth ensures you aren’t over-treated or under-treated for your specific condition.
Deep Dive for the Curious Patient: The Compensation Hypothesis
You do not need to understand this to be successfully treated, but it explains why your disease looks the way it does.
You may wonder why some patients only have mouth sores, while others have blisters over their entire body. This is explained by the Desmoglein Compensation Hypothesis [12].
The body uses Dsg1 and Dsg3 differently depending on the location:
- In the Mouth: The tissue is very dependent on Dsg3. There isn’t much Dsg1 to help out. If the immune system attacks Dsg3, the mouth “unglues” immediately [12][13].
- On the Skin: Both Dsg1 and Dsg3 are present. If the immune system only attacks Dsg3, the Dsg1 protein is strong enough to compensate and hold the skin together. This results in mucosal-dominant PV (mouth sores only) [12][14].
- Mucocutaneous PV: If the immune system attacks both Dsg1 and Dsg3, the skin loses all its structural support, leading to blisters on both the skin and the mouth [12].
Next: Find out how doctors use these biological markers in Decoding Your Diagnosis.
Common questions in this guide
What is acantholysis in Pemphigus Vulgaris?
How is Pemphigus Vulgaris different from Bullous Pemphigoid?
Why do my PV blisters only appear in my mouth?
Will Pemphigus Vulgaris blisters leave permanent scars?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my biopsy show suprabasal acantholysis, and how does this confirm my diagnosis of PV over other blistering conditions?
- 2.Based on my specific antibody profile, do I have the mucosal-dominant or the mucocutaneous form of PV?
- 3.How does the depth of my blisters (intraepidermal) affect the type of topical or systemic treatments you are recommending?
- 4.Since PV typically does not scar, what should I do if I notice permanent changes or scarring in my mouth or near my eyes?
- 5.Would you recommend an ELISA blood test to track my Desmoglein 1 and 3 levels as we begin treatment?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
The involvement of ADAM10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient.
Ivars M, España A, Alzuguren P, et al.
The British journal of dermatology 2020; (182(5)):1194-1204 doi:10.1111/bjd.18382.
PMID: 31370093 - 2
Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis.
Egu DT, Walter E, Spindler V, Waschke J
The British journal of dermatology 2017; (177(6)):1612-1618 doi:10.1111/bjd.15721.
PMID: 28600798 - 3
Esophageal involvement by pemphigus vulgaris resulting in dysphagia.
Cecinato P, Laterza L, De Marco L, et al.
Endoscopy 2015; (47 Suppl 1 UCTN()):E271-2 doi:10.1055/s-0034-1391905.
PMID: 26099087 - 4
Current status and prospects for the diagnosis of pemphigus vulgaris.
Nili A, Salehi Farid A, Asgari M, et al.
Expert review of clinical immunology 2021; (17(8)):819-834 doi:10.1080/1744666X.2021.1945925.
PMID: 34162306 - 5
Oral autoimmune vesicobullous diseases: Classification, clinical presentations, molecular mechanisms, diagnostic algorithms, and management.
Leuci S, Ruoppo E, Adamo D, et al.
Periodontology 2000 2019; (80(1)):77-88 doi:10.1111/prd.12263.
PMID: 31090146 - 6
Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
de Graauw E, Sitaru C, Horn M, et al.
Allergy 2017; (72(7)):1105-1113 doi:10.1111/all.13131.
PMID: 28135772 - 7
Update on IgG4-mediated autoimmune diseases: New insights and new family members.
Koneczny I
Autoimmunity reviews 2020; (19(10)):102646 doi:10.1016/j.autrev.2020.102646.
PMID: 32801046 - 8
Oral mucous membrane pemphigoid and pemphigus vulgaris-a retrospective two-center cohort study.
Sultan AS, Villa A, Saavedra AP, et al.
Oral diseases 2017; (23(4)):498-504 doi:10.1111/odi.12639.
PMID: 28084005 - 9
Mucocutaneous Diseases.
Kuten-Shorrer M, Menon RS, Lerman MA
Dental clinics of North America 2020; (64(1)):139-162 doi:10.1016/j.cden.2019.08.009.
PMID: 31735224 - 10
A 10-Year Observational Study on Treatment Approaches in Pemphigus and Pemphigoid.
Pereira CP, Santos R, Ferreira L, et al.
Acta stomatologica Croatica 2025; (59(2)):190-198 doi:10.15644/asc59/2/8.
PMID: 40641586 - 11
Treatment of pemphigus in Australia: Aligning current practises with global recommendations.
Somerville E, Gebauer K, Mclean-Tooke A
The Australasian journal of dermatology 2022; (63(2)):190-196 doi:10.1111/ajd.13804.
PMID: 35184283 - 12
Desmoglein compensation hypothesis fidelity assessment in Pemphigus.
Sielski L, Baker J, DePasquale MC, et al.
Frontiers in immunology 2022; (13()):969278 doi:10.3389/fimmu.2022.969278.
PMID: 36211362 - 13
Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology.
Ahmed AR, Carrozzo M, Caux F, et al.
Experimental dermatology 2016; (25(11)):839-846 doi:10.1111/exd.13106.
PMID: 27305362 - 14
Evaluation of the Importance of Immunological Profile for Pemphigus Vulgaris in the Light of Necessity to Modify Compensation Theory.
Öktem A, Hayran Y, Uysal Pİ, et al.
Acta dermatovenerologica Croatica : ADC 2018; (26(2)):100-104.
PMID: 29989864
This page explains the biology and diagnosis of Pemphigus Vulgaris for educational purposes. Always consult your dermatologist or healthcare provider for an official diagnosis and treatment plan.
Get notified when new evidence is published on Pemphigus vulgaris.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.